Solan Headlines

Cutting-edge CAR Technology at Creative Biolabs to Advance CAR-T/NK/MA Research

 Breaking News
  • No posts were found

Cutting-edge CAR Technology at Creative Biolabs to Advance CAR-T/NK/MA Research

January 20
19:00 2021
As chimeric antigen receptor technology developed, Creative Biolabs now can provide one-stop CAR-T/NK/MA therapy development services based on several modern platforms to global scientists.

New York, USA – January 19, 2021 – Chimeric antigen receptor (CAR) is a kind of basic immunotherapy. After nearly 25 years of development, it has shown great potential in the treatment of malignant tumors. With the continuous discovery of new specific tumor markers and the development of genetic engineering technology, CAR technology is becoming more and more mature, and will be widely used in clinical practice.

As a leading technology provider, Creative Biolabs has established the CellRapeutics™ CAR technology platform. The scientist team with accumulated experience of more than ten years is confident to provide all-embracing CAR-T therapy, CAR-NK therapy, and CAR-MA therapy development services.

• CAR-T Therapy Development Service

CAR-T cell therapy is a promising new way to get immune cells called T cells to fight cancer by changing them in the lab so they can find and destroy cancer cells.

Creative Biolabs offers high-quality custom service covering the entire CAR-T therapy development process, such as biomarker identification and selection, CAR design and construction, virus packaging and CAR gene delivery, and in vitro & in vivo assays. The service is expected to greatly assist related research, preclinical investigation, and clinical stage development.

• CAR-NK Therapy Development Service

Different from CAR-T therapy, CAR-NK therapy uses cells from donated umbilical cord blood, it can potentially be made ahead of time and frozen for storage. Recent clinical trials have proved the potential of CAR-NK cells to be “off-the-shelf” anti-cancer immunotherapeutic products.

Equipped with the most advanced CAR technology, and state-of-the-art CAR development platforms, Creative Biolabs is fully capable of offering a broad range of CAR-NK cell early development services, including biomarker identification and selection, design, construction, and analysis.

• CAR-MA Therapy Development Service

CAR macrophages (CAR-MA) present a novel tool for solid tumor treatment and open up the possibility of the development of new and exciting immunotherapeutic modalities. With the help of rich experience and scientific teams in CAR-T therapy, Creative Biolabs now offers one-stop services of CAR-MA.

The featured CAR-MA assay services can help provide cell therapies with fewer adverse events than traditional cell therapies. Different types of assays are available including bead engulfment assay, bites assay, eating assay, confocal imaging, quantification of whole cell internalization, quantification of bites internalization, and FRET assay.

More information about CAR-related services, as well as products, can be reached on

About Creative Biolabs

With more than 15 years’ history, Creative Biolabs has gathered talented scientists working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, Creative Biolabs specializes in the one-stop custom services for CAR-T cell development, TCR modified T cell development, CAR-MA therapy development, cancer vaccine development, drug discovery for CRS management, etc.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States

Related Articles